1型糖尿病残留C肽分泌对血糖控制及微血管并发症的临床影响
该研究在苏格兰1型糖尿病生物资源库队列(n=6076)中,平均随访5.2年,发现残留C肽分泌与更低的胰岛素剂量、HbA1c、酮症酸中毒住院风险及视网膜病变风险相关,且对严重低血糖的保护作用在C肽低至检测限(3 pmol/L)时仍持续存在。
要点
- C肽≥200 pmol/L者胰岛素剂量低27%,HbA1c低4.9 mmol/mol
- C肽≥200 pmol/L者酮症酸中毒住院风险HR 0.44,视网膜病变OR 0.51
- C肽30-<200 pmol/L者严重低血糖自报OR 0.56,低血糖住院HR 0.52
核心结论
- 在大型代表性队列中,即使极低水平的残留C肽分泌也可能对1型糖尿病具有临床获益。
研究设计与样本
- 基于苏格兰糖尿病研究网络1型糖尿病生物资源库(SDRNT1BIO)队列的6,076例1型糖尿病患者,平均随访5.2年。
- C肽采用非定时血样测量。
主要发现
- 校正发病年龄和病程后,C肽≥200 vs <5 pmol/L的效应:基线胰岛素剂量低27%(P=2×10^-39);随访期间HbA1c低4.9 mmol/mol(P=3×10^-13)。
- C肽≥200 vs <5 pmol/L:随访期间酮症酸中毒住院HR 0.44(P=0.0001);视网膜病变发病OR 0.51(P=0.0003)。
- C肽30-<200 vs <5 pmol/L:过去一年至少一次严重低血糖自报OR 0.56(P=6×10^-8);随访期间低血糖住院HR 0.52(P=0.03)。
- 对严重低血糖风险的影响在更低C肽水平即可检测到,且关系呈连续性直至检测限(3 pmol/L)。
临床怎么用
- 提示在1型糖尿病中,即使微量残留C肽也可能带来血糖控制和并发症方面的临床获益。
- 对保留或恢复胰岛功能干预试验的设计与评估具有启示意义。
局限性
- 与DCCT强化治疗队列随访研究不同,后者仅在C肽≥130 pmol/L时观察到对低血糖的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify the relationship of residual C-peptide secretion to glycemic outcomes and microvascular complications in type 1 diabetes. RESEARCH DESIGN AND METHODS: C-peptide was measured in an untimed blood sample in the Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) cohort of 6,076 people with type 1 diabetes monitored for an average of 5.2 years. RESULTS: In regression models adjusted for age at onset and duration, effect sizes for C-peptide ≥200 vs. <5 pmol/L were as follows: insulin dose at baseline, 27% lower (P = 2 × 10-39); HbA1c during follow-up, 4.9 mmol/mol lower (P = 3 × 10-13); hazard ratio for hospital admission for diabetic ketoacidosis during follow-up, 0.44 (P = 0.0001); odds ratio for incident retinopathy, 0.51 (P = 0.0003). Effects on the risk of serious hypoglycemic episodes were detectable at lower levels of C-peptide, and the form of the relationship was continuous down to the limit of detection (3 pmol/L). In regression models contrasting C-peptide 30 to <200 pmol/L with <5 pmol/L, the odds ratio for self-report of at least one serious hypoglycemic episode in the last year was 0.56 (P = 6 × 10-8), and the hazard ratio for hospital admission for hypoglycemia during follow-up was 0.52 (P = 0.03). CONCLUSIONS: These results in a large representative cohort suggest that even minimal residual C-peptide secretion could have clinical benefit in type 1 diabetes, in contrast to a follow-up study of the Diabetes Control and Complications Trial (DCCT) intensively treated cohort where an effect on hypoglycemia was seen only at C-peptide levels ≥130 pmol/L. This has obvious implications for the design and evaluation of trials of interventions to preserve or restore pancreatic islet function in type 1 diabetes.
引用
- Jeyam A, Colhoun H, McGurnaghan S, et al. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care. 2020. PMID: 33303639. doi:10.2337/dc20-0567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。